Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jul
27
2023
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Nov
10
2023
From Good Reprint Practices to SIUU Communications: What Firms Need to Know Sheppard, Mullin, Richter & Hampton LLP
Apr
21
2020
Telehealth and Online Prescribing: COVID-19 Triggers Changes to the Prescriber/Patient/Pharmacist Relationship Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2016
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2020
President Trump’s Executive Order Mandating the Purchase of U.S. Drugs Evokes Criticism Sheppard, Mullin, Richter & Hampton LLP
Oct
2
2020
FDA’s Proposed Rule on “Intended Use” Confirms Agency Will Rely on “Any Relevant Source” of Evidence Sheppard, Mullin, Richter & Hampton LLP
Dec
4
2020
Cannabis Gets Go-Ahead from House, But Still Faces Hurdles Before Federal Legalization Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2010
The FDA Transparency Initiative: Another One Way Street? Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2021
California Breaks New Ground With OCal: Answers to Key Questions About “Comparable-to-Organic” Cannabis Sheppard, Mullin, Richter & Hampton LLP
Mar
13
2018
Under the Radar Changes to Proposition 65 – OEHHA Issues New “Guidance” For Web Purchases (Is it an Illegal “Underground Regulation”?) Sheppard, Mullin, Richter & Hampton LLP
Feb
16
2022
Restructure This! Episode 3: Canada: Cannabis Boom or Bust? [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
1
2022
Treasury Department Recommends Antitrust Reform in Alcohol Markets Sheppard, Mullin, Richter & Hampton LLP
Mar
18
2022
OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2013
No Avoiding BPCIA (Biologics Price Competition and Innovation Act) For Biosimilars: No Patent Declaratory Judgment Action Before Biosimilars Application Is Filed Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2022
International Cooperation under China’s Proposed Implementing Rules for Human Genetic Resources Management Sheppard, Mullin, Richter & Hampton LLP
Jan
16
2014
Contaminated but Remediated Soil and Cortese Listing Does Not Compel Preparation of EIR (Environmental Impact Report) Sheppard, Mullin, Richter & Hampton LLP
Jun
20
2022
Supreme Court Saves Hospitals from $1.6B Cut to 340B Program Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET® Sheppard, Mullin, Richter & Hampton LLP
Jun
12
2014
Proposed Health Information Technology Strategy Aims to Promote Innovation Sheppard, Mullin, Richter & Hampton LLP
Dec
27
2022
FDA Expands Inspection Guidance to Apply to Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2019
Don’t Spill Your Trade Secrets: Protecting Your Competitive Advantage in the Food and Beverage Industry (Part 1 of 2) Sheppard, Mullin, Richter & Hampton LLP
Mar
7
2023
DEA Proposes Rule for Post-PHE Telemedicine Sheppard, Mullin, Richter & Hampton LLP
Jul
23
2019
Don’t Spill Your Trade Secrets: Protecting Your Competitive Advantage in the Food and Beverage Industry (Part 2 of 2) Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2023
Withdrawal of Drug Approval Highlights Risk of Accelerated Approval Pathway Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
New York Landlords May Get Stuck with the Bill for Unlicensed Cannabis Sticker Shops Sheppard, Mullin, Richter & Hampton LLP
Jun
21
2023
The Drug Price Negotiation Program Faces Pushback from Private and Public Industry Participants Sheppard, Mullin, Richter & Hampton LLP
Feb
3
2020
Intellectual Property Outlook: Cases and Trends to Follow in 2020 — PART 2 Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Postpones Ex-US Facility Inspections Sheppard, Mullin, Richter & Hampton LLP
Apr
14
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies (as of April 14) Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2024
Cannabis Rescheduling: HHS Findings and Legal Implications Sheppard, Mullin, Richter & Hampton LLP
May
27
2020
Impact Of COVID-19 On Illinois Cannabis Contracts — Do Force Majeure Clauses Provide A Defense To Non-Performance Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2024
FDCA Preemption: A Powerful Tool for Defending Class Actions Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2020
Using ADR for Cannabis Disputes Sheppard, Mullin, Richter & Hampton LLP
Sep
25
2020
FDA Update: The Latest on Vaccine Development, Inspections, and Conducting Clinical Trials During Covid-19 Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins